News

Clive Dix speaks to Proactive London's Andrew Scott following the news they've raised around £6.6mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates.

Clive Dix updates Proactive London's Andrew Scott on progress across the firm's portfolio.

He says they're very confident of delivering deals in the near future.

At least one biotechnology company that develops new drugs for a living has created its own virtual reality platform for drug discovery. Founded in 2007, C4X Discovery (C4XD) out of Manchester, England, is a small-cap public company that has developed its own VR platform called 4Sight.

Dr Craig Fox, Chief Scientific Officer of C4X Discovery #C4XD discusses their collaboration with PhoreMost to accelerate Parkinson's Disease drug discovery pipeline.
(Interview starts at 10 minutes 15 seconds)

Chemists at C4X Discovery are using the virtual reality technology behind popular game Fortnite to visualize the structure of complex molecules. The tool, called 4Sight, has already been used to create a drug that is now in development to treat addiction.

For U.K.-based C4X Discovery Holdings PLC, gaming engines are powering a more efficient drug-discovery process. The company uses the engines to discover molecules that help fight diseases like Alzheimer’s, Parkinson’s and ulcerative colitis, then licenses the resulting drugs to customers.

UK-based Pharmaceutical research firm C4X Discovery recently starting using Unreal Engine technology to visualize and manipulate 3-D molecules in virtual reality, with the potential to let scientists collaborate remotely in the virtual environment.

Need to find innovative medicines fuels new collaborations for UK small-caps

...Take C4X, a drug discovery and development company that has a wholly-owned drug pipeline but is also developing molecules in partnership with pharma, biotech and academia.

Clive Dix, chief executive, says large pharmaceutical companies “are crying out for innovation and are struggling to get enough of it in their own organisation to have the best molecules coming through. They’re therefore going to . . . smaller, more innovative companies and licensing products from them”.

Its proprietary technologies include a tool that analyses genetic databases, and another that determines the 3D shape of drug molecules while they are still at the test-tube stage.